LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study.

    Riva, Eloísa / Duarte, Patricio José / Valcárcel, Bryan / Remaggi, Guillermina / Murrieta, Ivan / Corzo, Ariel / Del Carpio, Daniel / Peña, Camila / Vásquez, Jule / Bove, Virginia / Teixeira, Larissa / Fleury-Perini, Guilherme / Yantorno, Sebastian / Samánez, César / Lopresti, Sergio / Altamirano, Milagros / Villela, Luis / Ruiz-Arguelles, Guillermo J / Ruiz-Delgado, Guillermo J /
    Montaño, Efreen / Verri, Verónica / Zamora Pérez, Elia / Pérez Jacobo, Fernando / Idrobo, Henry / Martínez-Cordero, Humberto / Beltran, Brady E / Ramírez, Jhoanna / Castillo, Jorge J / Malpica Castillo, Luis E

    JCO global oncology

    2022  Volume 8, Page(s) e2100380

    Abstract: Purpose: Waldenstrom Macroglobulinemia (WM) is a rare lymphoma with distinct clinical features, and data from Latin American patients are lacking. Therefore, we aim to investigate the clinical, therapy, and outcome patterns of WM in Latin America.: ... ...

    Abstract Purpose: Waldenstrom Macroglobulinemia (WM) is a rare lymphoma with distinct clinical features, and data from Latin American patients are lacking. Therefore, we aim to investigate the clinical, therapy, and outcome patterns of WM in Latin America.
    Methods: We retrospectively analyzed patients with WM diagnosed between 1991 and 2019 from 24 centers in seven Latin American countries. The study outcomes were overall survival (OS) and progression-free survival (PFS).
    Results: We identified 159 cases (median age 67 years, male 62%). Most patients (95%) were symptomatic at diagnosis. The International Prognostic Scoring System for WM (IPSSWM) at diagnosis was available in 141 (89%) patients (high-risk 40%, intermediate-risk 37%, and low-risk 23%). Twenty-seven (17%) patients were tested for MYD88
    Conclusion: In Latin America, the management of WM is heterogeneous, with limited access to molecular testing and novel agents. However, outcomes were similar to those reported internationally. We validated the IPSSWM score as a prognostic factor for OS and PFS. There is an unmet need to improve access to recommended diagnostic approaches and therapies in Latin America.
    MeSH term(s) Aged ; Humans ; Latin America/epidemiology ; Male ; Mutation ; Myeloid Differentiation Factor 88/genetics ; Myeloid Differentiation Factor 88/therapeutic use ; Retrospective Studies ; Waldenstrom Macroglobulinemia/drug therapy ; Waldenstrom Macroglobulinemia/therapy
    Chemical Substances Myeloid Differentiation Factor 88
    Language English
    Publishing date 2022-08-08
    Publishing country United States
    Document type Journal Article
    ISSN 2687-8941
    ISSN (online) 2687-8941
    DOI 10.1200/GO.21.00380
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma Registry.

    Biasoli, Irene / Castro, Nelson / Delamain, Marcia / Silveira, Talita / Farley, James / Pinto Simões, Belinda / Solza, Cristiana / Praxedes, Monica / Baiocchi, Otávio / Gaiolla, Rafael / Franceschi, Fernanda / Bonamin Sola, Caroline / Boquimpani, Carla / Clementino, Nelma / Fleury Perini, Guilherme / Pagnano, Kátia / Steffenello, Giovana / Tabacof, Jacques / de Freitas Colli, Gilberto /
    Soares, Andrea / de Souza, Carmino / Chiattone, Carlos Sérgio / Raggio Luiz, Ronir / Milito, Cristiane / Morais, José Carlos / Spector, Nelson

    International journal of cancer

    2017  Volume 142, Issue 5, Page(s) 883–890

    Abstract: Socioeconomic status (SES) is a well-known determinant of outcomes in cancer. The purpose of this study was to analyze the impact of the SES on the outcomes of Hodgkin lymphoma (HL) patients from the Brazilian Prospective HL Registry. SES stratification ... ...

    Abstract Socioeconomic status (SES) is a well-known determinant of outcomes in cancer. The purpose of this study was to analyze the impact of the SES on the outcomes of Hodgkin lymphoma (HL) patients from the Brazilian Prospective HL Registry. SES stratification was done using an individual asset/education-based household index. A total of 624 classical HL patients with diagnosis from January/2009 to December/2014, and treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine), were analyzed. The median follow-up was 35.6 months, and 33% were classified as lower SES. The 3-year progression- free survival (PFS) in higher and lower SES were 78 and 64% (p < 0.0001), respectively. The 3-year overall survival (OS) in higher and lower SES were 94 and 82% (p < 0.0001), respectively. Lower SES patients were more likely to be ≥ 60 years (16 vs. 8%, p = 0.003), and to present higher risk International Prognostic score (IPS) (44 vs. 31%, p = 0.004) and advanced disease (71 vs. 58%, p = 0.003). After adjustments for potential confounders, lower SES remained independently associated with poorer survival (HR = 3.12 [1.86-5.22] for OS and HR = 1.66 [1.19-2.32] for PFS). The fatality ratio during treatment was 7.5 and 1.3% for lower and higher SES (p = 0.0001). Infections and treatment toxicity accounted for 81% of these deaths. SES is an independent factor associated with shorter survival in HL in Brazil. Potential underlying mechanisms associated with the impact of SES are delayed diagnosis and poorer education. Educational and socio-economic support interventions must be tested in this vulnerable population.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/economics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Brazil ; Female ; Follow-Up Studies ; Hodgkin Disease/drug therapy ; Hodgkin Disease/economics ; Hodgkin Disease/mortality ; Humans ; Income ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Registries/statistics & numerical data ; Social Class ; Survival Rate ; Young Adult
    Language English
    Publishing date 2017-10-26
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218257-9
    ISSN 1097-0215 ; 0020-7136
    ISSN (online) 1097-0215
    ISSN 0020-7136
    DOI 10.1002/ijc.31096
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 478: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 576: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top